Roivant Sciences Ltd. License Agreements
4 Contracts & Agreements
- First Amendment to the License Agreement by and between Bayer Aktiengesellschaft and Pulmovant, Inc., dated as of September 22, 2023 (Filed With SEC on November 12, 2024)
- License Agreement by and between Bayer Aktiengesellschaft and Pulmovant, Inc., dated as of July 27, 2023 (Filed With SEC on November 12, 2024)
- Exclusive License Agreement by and between Eisai Co. Ltd. and Pharmavant 7 GmbH, dated as of November 24, 2021 (Filed With SEC on February 14, 2022)
- Third Amendment to Cross License Agreement, dated December 9, 2021, by and between Genevant Sciences GmbH and Arbutus Biopharma Corporation (Filed With SEC on December 22, 2021)
